2159 (2159) Fair Value & Analysis

Healthcare · Market cap HK$440M

2 2159 2159 · HK

PriceHK$1.62

Fair ValueHK$0.7200

Upside-55.6%

Quality64/100

Watch 2159 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.5400 – HK$0.9000

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price −1.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5900 – HK$2.15 · fair‑value band HK$0.5400 – HK$0.9000 · the HK$1.62 price screens above the HK$0.7200 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2159 (2159) currently trades at HK$1.62, while our model-based Fair Value estimate is HK$0.7200 — implying the stock looks roughly 55.6% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2159 generated revenue of HK$468M at a net margin of 2.1%. Revenue grew 88.5% year over year. It earns a return on equity of 7.8%. The balance sheet holds a net cash position of HK$44.9M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$468M

Revenue growth (YoY) +88.5%

Net margin 2.1%

Return on equity 7.8%

Free cash flow HK$2.5M FY2025

P/E ratio 32.4

More key figures

Operating margin 1.7%

EPS (TTM) HK$-0.0300

EPS growth (YoY) -21.3%

Net cash HK$44.9M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2159 reported revenue of HK$468M in FY2025 versus HK$708M in FY2021, a compound −9.8%/yr. Reported net income was HK$10.0M in FY2025, compounding +21.1%/yr from FY2021.

Revenue −9.8%/yr

FY21 HK$708M

FY22 HK$323M

FY23 HK$331M

FY24 HK$322M

FY25 HK$468M

Net income +21.1%/yr

FY21 HK$4.6M

FY22 −HK$89.2M

FY23 −HK$94.1M

FY24 −HK$45.2M

FY25 HK$10.0M

Is 2159 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$66.84	$21.63	-68%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2159 (2159) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.7200 versus a price of HK$1.62 — about −56% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2159?

Our model-based fair value for 2159 is HK$0.7200 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.62.

What is the quality score of 2159?

2159 has a Quality Score of 64/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2159 (2159)?

2159 reported trailing-twelve-month revenue of about HK$468M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2159?

The net profit margin of 2159 is about 2.1%, meaning it keeps roughly 2.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.